Posts by Sandra Ansanay-Alex
From Code to Conformity
This practical software development workshop for medical devices under EU MDR/IVDR and the AI Act is taking place on 18 November 2026 at Biopôle This free, full-day workshop with Firefinch, Lucendra MedTech Consulting and TÜV SÜD is designed to leave you with actionable insights to avoid costly rework, a clearer understanding of what regulators actually…
Read MoreNagi Bioscience and InVirtuoLabs join forces to bring whole-organism biology into AI drug discovery
Nagi Bioscience, an EPFL spin-off based at EPFL Innovation Park, has announced a new partnership with InVirtuoLabs, based in Ticino, an AI-native drug discovery company. The partnership will feed experimental data from the C. elegans worm into InVirtuoLabs’ AI models. InVirtuoLabs designs new molecules on its proprietary platform, which combines AI with molecular modeling. Nagi…
Read MoreGeneva Mass Spectrometry Day
The Geneva Mass Spectrometry Day is taking place on 10 December 2026 at Fondation Louis Jeantet in Geneva Organised by the Faculties of Science and Medicine at UNIGE, this event is aimed at technical staff, PhD students, postdoctoral researchers, researchers and group leaders. The discussions will highlight the research, services and mass spectrometry platforms available…
Read MoreDistalmotion Secures Up to $70 Million Term Loan to Accelerate US Expansion
Distalmotion, a global MedTech company based à Biopôle-Lausanne and focused on expanding access to robotic surgery in outpatient settings, announced that it has entered into a senior secured term loan facility of up to $70 million with Perceptive Advisors (“Perceptive”), a leading global healthcare investment firm. The financing provides additional capital to support Distalmotion’s continued…
Read MoreNeurosterix announces the success of a Phase I trial for NTX-253
The drug candidate, intended for the treatment of schizophrenia, is now set to enter Phase II. Addex holds a 20 per cent stake in the Plan-les-Ouates-based pharmaceutical company. Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company based in Geneva and focused on developing a portfolio of novel small molecule allosteric modulators for…
Read MoreBiodelphis Therapeutics, PolaSight and Swiss Soil each receive a Tech Seed loan
The Foundation for Innovation and Technology (FIT) is supporting three life sciences start-ups through Tech Seed loans. Biodelphis Therapeutics is receiving CHF 100’000 to advance its targeted treatment for osteoporosis. PolaSight has been awarded a loan of CHF 100’000 to prepare for the market launchof its scanner, which helps pathologists analyse tissue samples taken during…
Read MoreBioAlps Networking Day – Meet the Exhibitors
About fifteen exhibitors will be waiting for you at the BioAlps Networking Day on 19 November 2026 at Beaulieu Lausanne. They range from cantonal agencies and innovation campuses to research centres, global industry players and specialist service providers. Together, they offer a snapshot of the Swiss Health Valley’s ecosystem. Here’s who you can meet between…
Read MoreRelease Therapeutics Secures Non-Dilutive Innosuisse Funding
Release Therapeutics, a privately held Swiss BioMedTech company based at Campus Biotech in Geneva, announced that it has been awarded a CHF 500,000 Innovation Project grant from Innosuisse, the Swiss Innovation Agency, under an academic-industry partnership with the Faculty of Medicine, University of Geneva (UNIGE). MPS IIIA is a devastating, ultra-rare lysosomal storage disorder…
Read MoreCinainu Receives FDA Breakthrough Therapy Designation for Alopecia Areata
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to CINAINU® (LH-8), an investigational topical treatment for moderate-to-severe alopecia areata. Legacy Healthcare, a biopharmaceutical company based in Epalinges, Switzerland, announced the decision on October 13, 2026. The designation covers adults, adolescents and children aged 2 years and older. A botanical drug first…
Read MoreHUG Climbs to No. 1 in Switzerland in Newsweek’s Smart Hospitals Ranking
Geneva University Hospitals (HUG) are now Switzerland’s most advances hospital in the digital field. In the 2027 edition of Newsweek and Statista’s “World’s Best Smart Hospitals” ranking, published in October 2026, HUG jumped 37 places to 31st worldwide. That puts it 9th in Europe and first in Switzerland, a first for the Geneva institution. CHUV…
Read More